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Appetite and Body Weight Regulation: Minireview
Is It All in the Brain?
Satya P. Kalra species studied. Knowing whether the hypothalamic
NPY network is a component of the normal±natural ap-Department of Neuroscience
The University of Florida Brain Institute petite transduction pathway is fundamental for under-
standing the brain's control of appetite and body weight.University of Florida College of Medicine
Gainesville, Florida 32610 Evidence in favor of this implication is the abrupt in-
crease in NPY secretion before mealtime in the paraven-
tricular nucleus, one of the sites normally engaged in
generating appetite-evoking signals. This heightenedFew human diseases have spurred more public interest
secretion of NPY is maintained and appetite is sustainedrecently than obesity and an abnormal rate of body
for as long as food is withheld (Kalra et al., 1991). On theweight gain, the most prevalent nutritional disorders in
other hand, if NPY secretion is halted or its availability atdeveloped, industrialized nations. Obesity has reached
target sites is curtailed experimentally, appetite sub-epidemic status since, according to the Institute of Med-
sides despite a severe loss in body energy. Furthermore,icine, 59% of Americans are clinically obese or at least
continuous NPY receptor activation reproduces the nor-20% above their ideal body weight. This disease is a
mal pattern of intermittent feeding in satiated rats with-major contributor to the high rate of morbidity due to
out developing tolerance, and accelerates the rate ofincreased risk of cardiovascular diseases, including
body weight gain culminating in obesity that is indistin-stroke and hypertension, and diabetes. Whereas extra-
guishable from that produced experimentally or seenneous causes, such as overeating and/or reduced physi-
in genetic models (Kalra and Kalra, 1996). Given thesecal activity, undoubtedly underlie the increased inci-
results, researchers were surprised to find that a geneticdence of obesity, the notion that genetic abnormalities
knockout of NPY had no obvious body weight pheno-area contributing factor gainedan unprecedented boost
type. However, subsequent experiments have shownin the public interest with the cloning of the first major
genetic interactions of NPY with the product of the obobesity gene (ob) and characterization of the protein,
gene (see below), indicating that NPY is an importantleptin, that it encodes (Zhang et al., 1994). The possibility
element in the network (Erickson et al., 1996).that lack of leptin action in the brain may cause human
Whereas these demonstrations of temporal and site-obesity (Campfield et al., 1995) then provided the wake-
specific NPY secretion correlated with onset of the driveup call to the scientific community. Research exploring
to eat suggest that NPY could be a natural appetiteall aspects of the pathophysiology of obesity and eating
transducer, other requisite criteria such as identificationdisorders, along with new revelations that the brain
of NPY targets have been more elusive. Several at-strives on a minute-to-minute basis to regulate appetite
tempts, including microinjections and c-fos activationfor energy intake necessary for weight regulation (Bray
in target cells, have revealed a rather broad field of NPYand Ryan, 1996; Kalra and Kalra, 1996; Spiegelman and
action within the forebrain (Kalra and Kalra, 1996). TheFlier, 1996), has progressed at a dizzying pace.
two NPY receptor subtypes that presumably mediateAll living organisms require food (a nutritional supply)
NPY-induced feeding are NPY Y1 and/or a variant Y5for growth and maintenance. This constant need is met
receptor subtype, both of which are widely distributedthrough a highly regulated drive to eat evoked by the
within and outside the hypothalamus (Larhammar,sensation of hunger. Because the neural, metabolic, and
1997). The source of NPY that contributes selectivelyhormonal signals shown to affect ingestive behavior are
to appetite stimulation is also far from clear. Discretegenerally stable during the period preceding or at the
subpopulations of NPY-producing neurons located lo-onset of the drive to eat, there is a general consensus
cally in the arcuate nucleus (ARC) of the hypothalamusthat a negative energy balance, such as that provoked
and in remote areas in the brain stem make major projec-by fasting, dieting, or undernourishment, intensifies ap-
tions into NPY-responsive sites in the forebrain. Al-petite to prevent underconsumption, but it is unlikely by
though only the ARC NPY neurons show fluctuations initself to ªtriggerº the drive to eat. Recently, a discrete
preproNPY mRNA levels in fasted and food-restrictedappetite-driving or orexigenic network in the hypothala-
rats, this group of neurons cannot be unequivocally des-mus that transduces and releases appetite-stimulating
ignated as the exclusive source of NPY because thesesignals, and is tightly programmed by a host of environ-
fluctuations do not directly correlate with feeding be-mental, neural, and metabolic afferent endocrine sig-
havior.nals, has been elucidated (Figure 1). While the existence
Does NPY Act Alone in Brain Regulationof such a hypothalamic network emitting specific ap-
of Daily Intake?petite-stimulating neurotransmitters±neuromodulators
Although NPY is the most abundant neuropeptide in thehad been suspected for over 50 years, it was not until
hypothalamus, current morphological and experimentalthe discovery of the potent orexigenic action of neuro-
evidence suggests the involvement of an interconnectedpeptide Y (NPY; Clark et al., 1984) that understanding
orexigenic network of NPY, galanin, and opioids in thethis network has become a near reality.
forebrain (Figure 1). NPY may stimulate food intake onIs NPY a Naturally Occurring
its own and also via stimulation of the release of theAppetite Transducer?
other orexigenic peptides, opioids, and galanin (KalraExogenous NPY administration consistently stimulates
feeding under all circumstances and in every vertebrate et al., 1996). As is characteristic of regulated biological
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Figure 1. A Schematic Representation of the
Various Components of the Brain Neural Cir-
cuitry Involved in the Control of Appetite
(1), stimulatory; (2), inhibitory; NPY, Neuro-
peptide Y; NE, norepinephrine; GAL, galanin;
and VMH, ventromedial hypothalamus.
systems, redundancy is evident at another level. Neuro- period when there is normally little feeding activity, and
transmitters, such as norepinephrine and g-aminobu- during the lights-off period of normally robust eating.
tyric acid, coproduced with NPY in the brain stem and Seemingly, marked diminution of NPY availability at tar-
the ARC, respectively, stimulate feeding on their own get sites results in the development of supersensitivity
and interact with the NPY-induced response (Horvath to NPY so that amounts of exogenous NPY that are
et al., 1997). Whether these coexisting signals represent insufficient to evoke feeding in normal rats stimulate a
multiple overlapping appetite-stimulating systems or near normal drive for food. Thus, one can picture a
whether they are employed to different extents under vicious circle of internal and external environmental fac-
different circumstances remains to be determined. That tors that result in loss of the tight control on NPY neu-
this biological redundancy is vital for energy homeosta- rosecretion causing either overabundance or low abun-
sis and eventually species' survival is clearly evident in dance, both of which cause exaggerated and unregu-
two types of NPY knockout mice. When NPY knockout lated eating patterns and increased body weight. This
mice are crossed with the obese (ob/ob) mouse (Erick- revelation may partly account for the difficulties faced
son et al., 1996), the double mutant progeny have a by physicians in designing therapies to decrease the
body weight closer to normal than the ob mutant. This body weight of obese patients.
result not only substantiates the importance of the un- If the orexigenic network generates a powerful behav-
derlying role of NPY, but also strengthened the view that ioral drive, then two basic questions arise: what orches-
disruption in NPY signaling may contribute to human trates dissipation of appetite to terminate the ongoing
obesity. feeding, and are there signals that tonically restrainorex-
NPY and Body Weight Regulation igenic signals during the intermeal interval? Neither of
Normally, animals rigidly guard their daily body weight these two questions has been specifically addressed.
around a set point, which is vulnerable to genetic, envi-
Since lesions in the lateral hypothalamus produce inani-
ronmental (quality of macronutrients, energy expendi-
tion and wasting attributable to a lack of motivational
ture, and psychosomatic influence), and hormonal in-
drive to eat (Bray and Ryan, 1996), it comes as no sur-sults. The resultant altered caloric intake may culminate
prise that organisms have designed more than one wayin one of two extremes: excessive body weight gain and
to address these questions. Interestingly, as with theobesity, or anorexia and wasting. There is considerable
trigger for appetite, both termination and tonic restraintsupport for the hypothesis that the rigid body weight
of eating behavior may be chemically addressed, en-maintenance is attained through multiple satiety signals
compassing both the neural and hormonal pathways.that intervene to terminate an ongoing meal and also
In the forebrain, a spectrum of locally produced neuro-regulate the intermeal intervals (Bray and Ryan, 1996;
modulators can inhibit intake in various experimentalSpiegelman and Flier, 1996). Physiologically, this may
paradigms. It is possible that some of these may repre-be relevant, but now it appears that satiety signaling can
sent the physiologically relevant ªoffº switches. Unlikebe overwhelmed by an onslaught of orexigenic signals,
cholecystokinin, a well-studied putative satiety signal,especially NPY. Overabundance of NPY produces hy-
several of these anorectic neuromodulators seem to ex-perphagia and abnormal body weight gain (Bray and
ert their anti-appetite effects largely through interruptionRyan, 1996; Kalra et al., 1996). Intriguingly, low abun-
of NPY efflux and action at postsynaptic levels withindance of NPY in the hypothalamus, as that produced
the hypothalamus. This list includes peptide membersby lesions in the ventromedial hypothalamus (VMH), also
of the corticotropin-releasing factor family (Spina et al.,up-regulates appetite to the extent that animals eat
equally throughout the day, both during the lights-on 1996), glucagon-like peptide-1 (Turton et al., 1996), me-
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lanocyte-stimulating hormone acting through melano- hormonal signals are key components of the long-
sought peripheral negative feedback link that actscortin-4 receptors (Fan et al., 1997), and serotonin in-
terfering drugs, such as d-fenfluramine, the active com- through a central orexigenic network for weight control
(Figure 1).ponent of the currently in-vogue diet pill Redux, and the
other serotonin reuptake blocker, fluoxitine (Kalra and Whereas this identification of putative key facets of
the ªlipostatº theory generated an immediate all-roundKalra, 1996). One can now add to this list the cytokines,
such as ciliary neurotrophic factor, an endogenous ano- excitement, further validation through analysis of circu-
lating levels of leptin in rodents and humans has beenrectic and cachectic agent during infection and disease
that acts by blocking NPY synthesis, release, and post- less than encouraging. Contrary to expectations, circu-
lating leptin levels are generally at their lowest duringsynaptic action (Kalra et al., 1996, Soc. Neurosci. ab-
stract). the intermeal intervals and rise either as part of the
innate daily rhythm or long after initiation of intake. Fur-The amount of body fat can be regulated by various
peripheral hormonal signals. One of these, pancreatic thermore, a strong positive correlation between plasma
leptin levels and body fat mass has been found, sug-insulin, acts via the hypothalamus to control appetite
and energy expenditure (Bray and Ryan, 1996; Spiegel- gesting that leptin production is regulated by the mass
of adipocytes. The fact that circulating levels are highlyman and Flier, 1996). This large circulating protein is
transported across the blood±brain barrier endothelium variable among individuals and are either in the normal
range or elevated in obese individuals argues againstinto the cerebrospinal fluid by an active process, and
one of the central sites of its action to suppress feeding the leptin-deficiency hypothesis as the cause of unregu-
lated eating and obesity in most cases (Spiegelman andis the paraventricular nucleus (Kalra and Kalra, 1996).
Insulin suppresses NPY release from the nerve terminals Flier, 1996; Considine et al., 1996a, 1996b; Maffei et al.,
1996). It ispossible that defective transport to the centralrapidly enough to support the possibility that the post-
prandial rise in insulin may terminate NPY-dependent nervous system, extremely rapid development of resis-
tance, and/or tolerance to the action of leptin in theeating episodes. However, the efficacy of insulin as the
primary hormonal signal in body weight control has been hypothalamus may be common in obese individuals.
Further, unlike the receptor variants detected in dia-questioned because of the fact that hyperinsulinemia
generally accompanies hyperphagia and obesity in man betic, obese db/db mice, the OB-R appears to be no
different in eight obese and lean individuals examinedand experimental models.
The ªlipostatº hypothesis has been an enduring pro- so far (Considine et al., 1996a), giving rise to the idea
of a defective postreceptor downstream leptin signalposal to explain the tight control on body weight (Zhang
et al., 1994; Spiegelman and Flier, 1996). It predicts that transduction underlying the hypothalamic insensitivity
to leptin.secretions from fat cells may be the key signals to the
brain to regulate feeding and body fat deposition. One The VMH lesion-induced rodent obesity model pro-
vides clues to this puzzle of high leptin production con-of these secretory products is encoded by the recently
cloned mouse obese (ob) gene and its counterparts in comitant with unregulated phagia and excessive rate
of body weight gain (Dube et al., 1996, Soc. Neurosci.other species, including humans (Zhang et al., 1994).
This identification was followed in quick succession by abstract). Soon after the production of chemical lesions
with no apparent structural damage in the VMH andcharacterization of 16-kd protein, leptin (Leptos 5 thin),
establishing its efficacy in normalizing body weight and after electrolytic lesions in the VMH, leptin production
is exaggerated concomitant with reduced availabilityappetite in leptin-deficient ob/ob mice by systemic and
central injections (Campfield et al., 1995; Spiegelman of NPY in the paraventricular nucleus and loss of the
regulated daily pattern of feeding (Spiegelman and Flier,and Flier, 1996), and most recently cloning of its receptor
(Tartaglia et al., 1995). The leptin receptor (OB-R), a 1996; Dube et al., 1996, Soc. Neurosci. abstract; Kalra
et al., 1996). The resultant hyperphagia and steady gainproduct of the db gene, which has been long believed to
encode the receptor for a weight-controlling hormone, is in weight, as mentioned above, may be a consequence
of rapid development of NPY receptor supersensitivityexpressed as various splice variants in the rodent and
human hypothalamus (Considine et al., 1996a; Lee et (Figure 1; Dube et al., 1996, Soc. Neurosci. abstract;
Kalra et al., 1996). Thus, thorough examination of theal., 1996; Mercer et al., 1996).
Significant new insights into the relationship between cellular and molecular bases of the shifts in receptor
dynamics of orexigenic signals accompanying weightperipheral signals, insulin, and leptin, and their impact
on theorexigenic network (Figure 1) have provided some disorders is warranted.
Notwithstanding these complexities, a neural timingcritical missing pieces in the ªlipostatº puzzle. Insulin
up-regulates leptin synthesis and release from adipo- mechanism also operates upstream from the orexi-
genic network in the daily management of energy ho-cytes, and leptin has been shown to cross the blood±
brain barrier via the parenchymal compartment (Bray meostasis (Figure 1). Although the precise anatomical
boundaries are not clearly defined, this device is likelyand Ryan, 1996; Spiegelman et al., 1996). An important
central action of leptin is likely to be inhibition of NPY to be composed of a group of neurons that integrate
incoming internal and external environmental informa-release and synthesis in the ARC of the hypothalamus
and possibly inhibition of the postsynaptic appetite- tion for the timely onset of the drive to eat. Whether this
network operates independently as evident in primates,stimulating effects of NPY (Stephens et al., 1995). The
findings that insulin and leptin each inhibit NPY release or whether it is entrained to the circadian timekeeper,
the hypothalamic suprachiasmatic nucleus, as in mostand that insulin has the potential to up-regulate leptin
output together support the likelihood that these two other mammals, remains to be ascertained. Intriguingly,
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Spiegelman, B.M., and Flier, J.S. (1996). Cell 87, 377±389.the VMH has also been suspected as an integrated con-
Spina, M., Merlo-Pich, E., Chau, R.K.W., Basso, A.M., Rivier, J., Vale,stituent of the timing mechanism because neural dam-
W., and Koob, G.F. (1996). Science 273, 1561±1564.age at this site, as that seen after destruction of the
Stephens, T.W., Babinski, M., Bristow, P.K., Bue-Vallesky, J.M., Bur-suprachiasmatic nuclei (Nagai et al., 1978), results in
gett, S.G., Craft, L., Hale, J., Hoffman, J., Hsiung, H.M., Krianciunas,loss of regulated feeding.
A., Mackellar, W., Rosteck, P.R., Jr., Schoner, B., Smith, D., Tinsley,
A distinct neural circuitry in the brain is clearly involved F.C., Zhang, X.Y., and Heiman, M. (1995). Nature 377, 530±532.
in the control of appetite and body weight gain (Figure
Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J.,
1). At least four basic elements of this circuitry have Deos, R., Prichard, G.J., Campfield, L.A., Clark, F.T., Deeds, J., Muir,
been deciphered, with only the NPYergic component C., Sanker, S., Moriarty, A., Moor, K.J., Smutko, J.S., Mays, G.G.,
Woolf, E.A., Monroe, C.A., and Tepper, R.I. (1995). Cell 83, 1263±of the orexigenic network as the target for peripheral
1277.hormones to exert a regulatory tonic restraint on NPY
Turton, M.D., O'Shea, D., Gunn, I., Beak, S.A., Edwards, C.M.,secretion. Consequently, the important task ahead is
Meeran, K., Choi, S.J., Taylor, G.M., Heath, M.M., Lambert, P.D.,to trace the signal transfer pathways among the three
Wilding, J.P.H., Smith, D.M., Chatel, M.A., Herbert, J., and Bloom,interactive circuits that mediate the escape from the
S.R. (1996). Nature 397, 69±72.
inhibitory influence of the VMH and/or anorectic signals
Zhang, Y., Provena, R., Maffei, M., Barone, M., Leopold, L., and
for the release of orexigenic signals. Additionally, new Friedman, J.R. (1994). Nature 372, 425±432.
revelations that both over- and underexpression of hy-
pothalamic NPY result in unregulated eating and body
weight gain, in conjunction with resistance to insulin
and leptin, underscore a new rationale for designing
therapeutic strategies to control appetite and body
weight. Seemingly, the efficacy of anti-appetite drugs
will depend both on their effectiveness to curtail the
availability of orexigenic messenger molecules at the
target sites while preventing the development of recep-
tor supersensitivity.
Selected Reading
Bray, G.A., and Ryan, D.H. (1996). Molecular and Genetic Aspects
of Obesity, Vol. 5. (Baton Rouge: Louisiana State University Press),
pp. 1±682.
Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P.
(1995). Science 269, 546±549.
Clark, J.T., Kalra, P.S., Crowley, W.R., and Kalra, S.P. (1984). Endo-
crinology 115, 427±429.
Considine, R.V., Considine, E.L., Wilham, C.J., Hyde, T.M., and Caro,
J.S. (1996a). Diabetes 19, 992±994.
Considine, R.V., Sinha, M.K., Heiman, M.L., Krianciunas, A., Ste-
phens, T.W., Nyce, M.R., Ohannesian, D., Marco, C.C., McKee, L-J.,
Baur, T.L., and Caro, J.D. (1996b). N. Engl. J. Med. 334, 292±295.
Erickson, J.C., Hollopeter, G., and Palmiter, R.D. (1996). Science
274, 1704±1707.
Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.J., and Cone, R.D.
(1997). Nature 385, 165±168.
Horvath, T.L., Bechmann, I., Naftolin, F., Kalra, S.P., and Leranth,
C. (1997). Brain Res. 756, 283±286.
Kalra, S.P., and Kalra, P.S. (1996). Curr. Sci. 3, 157±163.
Kalra, S.P., Dube, M.G., Sahu, A., Phelps, C., and Kalra, P.S. (1991).
Proc. Natl. Acad. Sci. USA 88, 10931±10935.
Kalra, S.P., Sahu, A., Dube, M.G., Bonavera, J.J., and Kalra, P.S.
(1996). In: Molecular and Genetic Aspects of Obesity. (Baton Rouge:
Louisiana State University Press), pp. 219±232.
Larhammar, D. (1997). In: Neuropeptide Y and Drug Development,
L. Grundemar and S. R. Bloom, eds. (New York: Academic Press),
pp. 87±103.
Lee, G.H., Proenca, R., Montez, J.M., Carroll, K.M., Davishzadeh,
J., Lee, J.I., and Friedman, J.M. (1996). Nature 359, 632±635.
Maffei, M., Halaas, J., Ravussin, E., Pratley, R.E., Lee, G.H., Zhang,
Y., Fei, H., Kim, S., Lallone, R., Raganathan, S., Kern, P.A., and
Friedman, J.M. (1995). Nature Med. 1, 1155±1161.
Mercer, J.G., Hoggard, N., Williams, L.M., Lawrence, C.B., Hannah,
L.T., Morgan, P.J., and Trayburn, P. (1996). J. Neuroendocrinol. 8,
733±735.
Nagai, K., Nishio, T., Nakagawa, H., Nakamura, S., and Fukuda, Y.
(1978). Brain Res. 142, 384±389.
